|
| 33171487 | Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. | Blood | 2021 |
| 33602316 | Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma. | Exp Hematol Oncol | 2021 |
| 34108263 | Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling Pathways. | Mol Cancer Ther | 2021 |
| 32720828 | Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience. | Leuk Lymphoma | 2020 |
| 32083160 | Plasmablastic lymphoma in an HIV patient with cutaneous presentation: A case of remarkable remission in a typically refractory disease. | JAAD Case Rep | 2020 |
| 33062232 | Low dose continuous lenalidomide in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma: a retrospective case series. | Ther Adv Hematol | 2020 |
| 32973968 | ATM inhibition overcomes resistance to histone deacetylase inhibitor due to p21 induction and cell cycle arrest. | Oncotarget | 2020 |
| 31231778 | Targeting Translation of mRNA as a Therapeutic Strategy in Cancer. | Curr Hematol Malig Rep | 2019 |
| 31471376 | Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study. | Blood | 2019 |
| 27984643 | Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma. | Br J Haematol | 2018 |
| 29475723 | Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. | Lancet Oncol | 2018 |
| 29276022 | Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial. | Lancet Oncol | 2018 |
| 29141948 | A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. | Blood | 2018 |
| 27784673 | Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies. | Blood | 2017 |
| 28220479 | A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab. | Br J Haematol | 2017 |
| 28341730 | Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant <i>MYD88</i> and wildtype <i>CD79</i>. | Haematologica | 2017 |
| 29248135 | Metabolic symbiosis in cancer and its therapeutic implication. | Semin Oncol | 2017 |
| 28738754 | Pralatrexate: a comprehensive update on pharmacology, clinical activity and strategies to optimize use. | Leuk Lymphoma | 2017 |
| 27899158 | High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy. | J Hematol Oncol | 2016 |
| 26634782 | Will new drugs change the standard of care for patients with mantle cell lymphoma? | Expert Rev Anticancer Ther | 2016 |
| 25355930 | The novel IKK2 inhibitor LY2409881 potently synergizes with histone deacetylase inhibitors in preclinical models of lymphoma through the downregulation of NF-κB. | Clin Cancer Res | 2015 |
| 25677697 | Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma. | Clin Cancer Res | 2015 |
| 23155186 | Brentuximab vedotin. | Clin Cancer Res | 2013 |
| 22700864 | New strategies in the treatment of mantle cell lymphoma. | Clin Cancer Res | 2012 |
| 16864733 | Images in cardiovascular medicine. Masking inferior infarction by anterior myocardial injury. | Circulation | 2006 |
| 17044924 | The research rotation: competency-based structured and novel approach to research training of internal medicine residents. | BMC Med Educ | 2006 |
| 16738548 | Global analysis of gene function in yeast by quantitative phenotypic profiling. | Mol Syst Biol | 2006 |
| 15834151 | Multiple endonucleases function to repair covalent topoisomerase I complexes in Saccharomyces cerevisiae. | Genetics | 2005 |
| 16380504 | Identification of mitogen-activated protein kinase signaling pathways that confer resistance to endoplasmic reticulum stress in Saccharomyces cerevisiae. | Mol Cancer Res | 2005 |
| 15575969 | Integrating phenotypic and expression profiles to map arsenic-response networks. | Genome Biol | 2004 |
| 11553705 | ADY1, a novel gene required for prospore membrane formation at selected spindle poles in Saccharomyces cerevisiae. | Mol Biol Cell | 2001 |
| 9128252 | The Saccharomyces cerevisiae kinesin-related motor Kar3p acts at preanaphase spindle poles to limit the number and length of cytoplasmic microtubules. | J Cell Biol | 1997 |